CSTL Earnings Prediction
The chart below shows how CSTL performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CSTL sees a -7.19% change in stock price 10 days leading up to the earnings, and a +0.56% change 10 days following the report. On the earnings day itself, the stock moves by +0.16%. This data can give you a slight idea of what to expect for the next quarter's release.
CSTL Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
85.78M
39.50%
-1.40%
Gross Margin
79.16%
1.62%
-1.94%
Operating Margin
5.92%
137.76%
2.78%
Net Margin
2.65%
123.60%
-74.15%
EPS
0.08
130.77%
-74.19%
No Data Available
CSTL Earnings Analysis
Castle Biosciences, Inc. Common Stock Corporation (CSTL.O) Earnings Conference Call
Positive
Strong Revenue and Volume Growth: Castle Biosciences delivered a strong quarter, growing revenue by 39% and total test report volume by 41% over the third quarter of 2023.
Positive Cash Flow Achievement: The company achieved positive cash flow and earnings, highlighting the operating leverage in their business model that has continued to drive strong financial performance.
Balance Sheet Strength: Castle has substantial balance sheet capacity allowing for investments in business for long-term growth and to continue efforts to drive shareholder value.
Revenue Guidance Increase: The company raised its full year 2024 revenue guidance range to be between $320 million and $330 million, reflecting year-over-year growth of 45% to 50%.
EBITDA Improvement Quarter-over-Quarter: In the third quarter of 2024, adjusted EBITDA was $21.6 million compared to $6.6 million for the comparable period in 2023, an improvement of $15.1 million.
Negative
Revenue Decline Analysis: Revenue decreased by 39% compared to the third quarter of 2023, totaling $85.8 million.
Operating Expenses Increase: Operating expenses increased to $80.7 million from $71.1 million in the third quarter of 2023, primarily due to higher travel and transportation costs.
Sales and Marketing Expenses Increase: Sales and marketing expenses rose to $29.8 million in the third quarter of 2024, compared to $28.5 million in the same period of 2023.
R&D Expense Decrease: R&D expenses were $12.3 million compared to $12.9 million for the same period in 2023, indicating a slight decrease.
Net Income Improvement: Net income for the third quarter of 2024 was $2.3 million, a significant drop from a net loss of $6.9 million in the third quarter of 2023.
CSTL FAQs
How does CSTL typically perform around its earnings report dates?
Is Castle Biosciences, Inc. (CSTL) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
CSTL Earning Call Sentiment
Castle Biosciences, Inc. (CSTL) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
CSTL.O
2.66%Positive
The earnings call summary and Q&A indicate strong financial performance, with significant revenue growth and improved profitability. The raised revenue guidance and positive net income transition are strong indicators of future growth. Despite minor supply chain challenges and economic factors, the company maintains a robust cash position and operational efficiency. The Q&A section shows management's confidence in their strategic initiatives, with no major concerns from analysts. Overall, the positive financial metrics and optimistic guidance suggest a positive stock price movement in the short term.